Comparative Pharmacology
Head-to-head clinical analysis: CYCLAFEM 0 5 35 versus OVRAL 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLAFEM 0 5 35 versus OVRAL 28.
CYCLAFEM 0.5/35 vs OVRAL-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing norethindrone (progestin) and ethinyl estradiol (estrogen). Inhibits gonadotropin release, suppressing ovulation. Increases cervical mucus viscosity and alters endometrium, reducing sperm penetration and implantation.
Combination oral contraceptive: suppresses gonadotropin release via estrogen and progestin, inhibiting ovulation, thickening cervical mucus, and altering endometrial lining.
One tablet (0.5 mg norethindrone/35 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 placebo days (or no tablets) per cycle.
One tablet (norgestrel 0.3 mg, ethinyl estradiol 0.03 mg) orally once daily for 21 consecutive days, followed by 7 days of placebo.
None Documented
None Documented
Terminal elimination half-life of norethindrone is 5-14 hours (mean 7.6 hours); ethinyl estradiol half-life is 7-20 hours (mean ~13 hours). Steady-state is achieved within 5-7 days.
Ethinyl estradiol: terminal half-life 13-27 hours (mean ~17 hours); norgestrel: terminal half-life 11-45 hours (mean ~24 hours). Clinical context: steady-state reached within 5-7 days; accumulation minimal with daily dosing.
Renal excretion accounts for approximately 50-60% of the dose (as metabolites), with 30-40% excreted in feces via biliary elimination. Unchanged drug is minimal in urine.
Renal: ~40% as metabolites; fecal: ~60% via biliary excretion, primarily as glucuronide and sulfate conjugates.
Category C
Category C
Oral Contraceptive
Oral Contraceptive